Antioxidant, α-glucosidase inhibitory and in vitro antitumor activities of coumarin-benzothiazole hybrids

Abstract

Coumarin-benzothiazole hybrids are antitumor agents based on their antioxidant and α-glucosidase inhibitory activities. Compounds 5a-c were selected by National Cancer Institute (NCI), USA, to be screened for antitumor activity at a single dose (10 μm) against a panel of 60 cancer cell lines. The most active compound 5c was further screened at a five-dose level by NCI. Compound 5c displays half maximal growth inhibition (GI50) values of 0.24 and 0.33 μm against central nervous system (CNS) cancer (SNB-75) and ovarian cancer (OVCAR-4) cell lines, respectively. Compounds 5a-c were also screened for their antioxidant and α-glucosidase inhibitory activities.